The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...